Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New supplement youniqor under safety review in older adults

NCT ID NCT07442097

Knowledge-focused Sponsor: YOXLO B.V. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study checks if the nutritional supplement Youniqor is safe for healthy adults aged 60 to 80. Sixteen participants will take it daily for 8 weeks and have regular health checks, including blood tests and heart monitoring. The goal is to see if any side effects occur and how well people tolerate the supplement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 16 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

60 to 80 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) between 22.5 and 29.9 kg/m², inclusive. * High-sensitivity C-reactive protein (hsCRP) levels between 0.7 and 5.0 mg/L, inclusive. * Willingness to provide written informed consent. * Willingness to comply with all study procedures and follow-up visits. * Willingness to avoid major lifestyle changes, including new structured physical training or cognitive training targeting study endpoints, during the study period. Exclusion Criteria: * Presence of chronic, inflammatory, or cardiometabolic disease requiring daily medication. * Uncontrolled diabetes mellitus (fasting blood glucose ≥126 mg/dL). * Hypertension. * Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m². * Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2× the upper limit of normal. * White blood cell count \<3500/mm³. * Ongoing or recent acute infection within 2 weeks prior to screening. * Vaccination within 4 weeks prior to screening. * Known allergy or intolerance to N-acetyl-L-cysteine (NAC) or glycine. * Participation in another clinical trial within 90 days prior to screening. * Current or recent use of systemic corticosteroids, immunosuppressants, or chronic pain medications. * neurodegenerative, neurological, or major psychiatric disorders. * History of alcohol or drug abuse based on medical history, physical examination, or investigator judgment. * Current smokers. * Any other condition which, in the opinion of the investigator, may interfere with study participation or safety.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aging, healthy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aging, healthy

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    1 site. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Vedic Lifesciences Pvt. Ltd.

    RECRUITING

    Pune, Maharashtra, 411045, India

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.